Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables Refunds
Ratios

Trinity Biotech (TRIB) Accumulated Depreciation & Amortization (2016 - 2018)

Historic Accumulated Depreciation & Amortization for Trinity Biotech (TRIB) over the last 5 years, with Q4 2018 value amounting to -$48.5 million.

  • Trinity Biotech's Accumulated Depreciation & Amortization fell 1108.51% to -$48.5 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$48.5 million, marking a year-over-year decrease of 1108.51%. This contributed to the annual value of -$48.5 million for FY2018, which is 1108.51% down from last year.
  • Trinity Biotech's Accumulated Depreciation & Amortization amounted to -$48.5 million in Q4 2018, which was down 1108.51% from -$43.6 million recorded in Q4 2017.
  • In the past 5 years, Trinity Biotech's Accumulated Depreciation & Amortization registered a high of -$22.4 million during Q4 2015, and its lowest value of -$48.5 million during Q4 2018.
  • In the last 4 years, Trinity Biotech's Accumulated Depreciation & Amortization had a median value of -$39.2 million in 2016 and averaged -$37.3 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first tumbled by 5485.86% in 2016, then crashed by 1108.51% in 2018.
  • Over the past 4 years, Trinity Biotech's Accumulated Depreciation & Amortization (Quarter) stood at -$22.4 million in 2015, then tumbled by 54.86% to -$34.7 million in 2016, then fell by 25.66% to -$43.6 million in 2017, then dropped by 11.09% to -$48.5 million in 2018.
  • Its Accumulated Depreciation & Amortization was -$48.5 million in Q4 2018, compared to -$43.6 million in Q4 2017 and -$34.7 million in Q4 2016.